

FIG. 1



FIG. 2



FIG. 3


GEO
HYB165
HYB165+ PACLITAXEL
PACLITAXEL
HYB165 = 0.5μM
PACLITAXEL=1; 5; 10 nM(a-c)
PERCENT GROWTH INHIBITION
100
80
60
40
20
0
a
b
c

FIG. 4



FIG. 5



FIG. 6



FIG. 7



FIG. 8



FIG. 9



HYB 165 = 0.1μM (a-d) 0.5μM9 (e-h)
DOCETAXEL = 0.01; 0.03; 0.1; 0.3nM
HYB 508 = 0.5μM (i-l)

FIG. 10



HYB 165 = 0.1μM (a-d) 0.5μM (e-h)
DOCETAXEL = 0.01; 0.03; 0.1; 0.3nM
HYB 508 = 0.5μM (i-l)

FIG. 11



FIG. 12



FIG. 13


EFFECT OF HYB165 OR HYB508 ON
ZR-75.1 BREAST CARCINOMA CELL GROWTH
PERCENT OF CONTROL
120
100
80
60
40
20
0
0.1
0.5
1.0
2.5
OLIGO CONCENTRATION(μM)
HYB165
HYB295

FIG. 14

EFFECT OF HYB165 AND CONTROL HYB295 ON SOFT AGAR GROWTH OF GEO COLON CANCER CELLS



FIG. 15



FIG. 16A



FIG. 16B


TUMOR VOLUME (cm3)
0
1
2
3
4
0
10
20
30
40
50
60
70
80
90
100
110
DAYS
CONTROL
TAXOL
AS RIa
TAXOL+AS RIa
SCRAMBLE
TAXOL+SCRAMBLE

FIG. 17A


CONTROL
TAXOL
AS RIα
COMBINATION
PERCENT OF SURVIVING MICE
100
80
60
40
20
0
0
2
4
6
8
10
12
14
16
WEEKS

FIG. 17B

TABLE: HISTOCHEMICAL ANALYSIS OF GEO TUMORS FOLLOWING TREATMENT WITH TAXOL AND/OR DIFFERENT ORAL MBOs.

	TUMOR SIZE (cm^3)	Ki67	RIα	AR	TGFα	p27	VESSELS
CONTROL	1.49	40%	70%	85%	50%	10%	15
TAXOL	0.80	20%	60%	70%	50%	10%	5
HYB165	1.02	28%	35%	50%	20%	15%	3
SCRAMBLE	1.39	30%	60%	85%	50%	8%	14
HYB165 + TAXOL	0.4	6%	15%	25%	30%	25%	0
SCRAMBLE + TAXOL	0.81	28%	60%	70%	50%	8%	7

ANALYSIS WAS PERFORMED AFTER THE 2nd CYCLE OF TREATMENT (ON DAY 27).
NUMBERS REPRESENT THE PERCENTAGE OF POSITIVE CELL STAINING FOR EACH ANTIGEN.

FIG. 18